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Abstract: Huntington disease (HD) is a dominantly inherited progressive neurological  disease 
characterized by chorea, an involuntary brief movement that tends to flow between body regions. 
HD is typically diagnosed based on clinical findings in the setting of a family history and 
may be confirmed with genetic testing. Predictive testing is available to those at risk, but only 
 experienced clinicians should perform the counseling and testing. Multiple areas of the brain 
degenerate mainly involving the neurotransmitters dopamine, glutamate, and γ-aminobutyric acid. 
Although pharmacotherapies theoretically target these neurotransmitters, few well-conducted 
trials for symptomatic or neuroprotective interventions yielded positive results. Tetrabenazine 
(TBZ) is a dopamine-depleting agent that may be one of the more effective agents for reducing 
chorea, although it has a risk of potentially serious adverse effects. Some newer antipsychotic 
agents, such as olanzapine and aripiprazole, may have adequate efficacy with a more favorable 
adverse-effect profile than older antipsychotic agents for treating chorea and psychosis. This 
review will address the epidemiology and diagnosis of HD as background for understanding 
potential pharmacological treatment options. Because TBZ is the only US Food and Drug 
Administration-approved medication in the United States for HD, the focus of this review will 
be on its pharmacology, efficacy, safety, and practical uses. There are no  current treatments to 
change the course of HD, but education and symptomatic therapies can be  effective tools for 
clinicians to use with patients and families affected by HD.
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Introduction
Huntington disease (HD) is a hereditary, progressive neurodegenerative disease  clinically 
characterized by abnormal involuntary movements, behavioral  disturbance, cognitive 
dysfunction, and psychiatric disease. The disease is caused by a CAG ( glutamine) 
trinucleotide expansion in exon 1 of the huntingtin (htt) gene at the  location 4p16.9.1 
The function of htt is not known, but it may be involved in internal cell  signaling, 
maintenance of cyclic adenosine monophosphate response element binding protein, 
and preventing neuronal toxicity.2 Early evidences suggest that the binding of the Ras 
homologue enriched in striatum (Rhes) protein to htt may be  necessary to cause cellu-
lar toxicity.3 However, why the protein causes cellular toxicity in adulthood is not well 
understood. Recent evidence suggests that the interaction of the group 1 metabotropic 
glutamate receptors and htt protein may be at the root of delayed onset.4
Although there is no established treatment to delay the onset or forestall the  progression 
of HD, symptomatic treatment of chorea may be beneficial in some  individuals, as it may 
have a favorable effect on motor function, quality of life, and safety.5–7
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Pathologically, HD is associated with diffuse loss of 
neurons, particularly involving the cortex and the  striatum. 
Medium spiny neurons in the striatum that contain 
γ-aminobutyric acid (GABA) and enkephalin are impacted 
early in the disease, and are the primary neurons targeted in 
HD. These neurons typically project into the lateral globus 
pallidus. Then, there is progression to the remainder of the 
basal ganglia with subsequent dissemination,  including cor-
tex and substantia nigra. There are intranuclear and cytoplas-
mic inclusions of the htt aggregate. Huntingtin is cross-linked 
with other soluble htt to form the inclusion bodies in neurons. 
It is not known if the accumulation of htt conglomerate results 
in cell death, or if the soluble form of the protein is the toxic 
form.8,9 Dopamine, glutamate, and GABA are thought to be 
the most involved neurotransmitters in HD and are targeted 
for treatment (Table 1).10–23
There are multiple theories on the pathogenesis of HD. It 
is likely that more than 1 process may be occurring at once, 
but there is evidence to support multiple individual mecha-
nisms, including toxic neuronal aggregates, transcriptional 
dysregulation, excitotoxicity, mitochondrial dysfunction with 
altered energy metabolism, and changes in axonal transport 
and synaptic dysfunction (Table 2).24–30,31
epidemiology
Most European populations show a prevalence rate of 4–8 
cases per 100,000, and HD may be frequently seen in India 
and parts of Central Asia.32 More recent studies in other 
European nations have confirmed this prevalence rate.33,34 
HD is notably rare in Finland and Japan, but data for Eastern 
Asia and Africa are inadequate. Outside of Venezuela, there 
are little epidemiological studies of HD in Hispanic popula-
tions. A recent study found a slightly higher prevalence rate 
than expected and higher proportion of juvenile cases in 
Mexico.35 There are also well-known large populations of 
patients with HD in Scotland and the Lake Maracaibo region 
of Venezuela.36,37 The disorder may be underestimated in the 
Black American population. There have been no widespread 
epidemiological studies of HD in the United States since the 
wide availability of genetic testing, but it is estimated that 
approximately 25,000–30,000 individuals have manifest 
HD and a further 150,000–250,000 individuals are at risk 
for HD.38
Men and women are affected equally and typically 
become symptomatic in the third and fourth decades. The 
symptoms of HD can start at any age ranging from 1 to 
90 years. Approximately 5%–10% of cases are classified 
as juvenile onset, with symptoms starting before the age of 
20 years. The vast majority of juvenile cases are inherited 
paternally, and instead of chorea, patients may exhibit more 
parkinsonian signs of bradykinesia, dystonia, tremors, and 
cognitive deficit.39 When patients exhibit more hypokinetic 
features (bradykinesia and dystonia) vs hyperkinetic features 
(chorea), they are said to have the Westphal variant of HD.
Diagnosis
HD is diagnosed based on the presence of typical motor 
findings as measured by the Unified Huntington’s Disease 
Table 1 Neurotransmitters involved in the pathogenesis of 
Huntington disease
Receptor Location Stage of disease
Adenosine  
A2A
Striatum, GPe Preclinical to advanced
Cannabinoid Striatum, GPe Preclinical to advanced
Dopamine D1 Striatum, substantia nigra Clinical diagnosis to advanced
Dopamine D2 Caudate, putamen Prodromal
Dynorphin Striatum emergence of dystonia
enkephalin Striatum emergence of chorea
GABA Striatum Advanced
Glutamate Cortical Preclinical to advanced
Substance P Striatum emergence of dystonia
Abbreviations: GPe, globus pallidus externa; GABA, γ-aminobutyric acid.
Table 2 Potential pathways for pathogenesis of Huntington 
disease
Neuronal aggregates
Neuronal intracytoplasmic and intranuclear inclusions containing 
mutant huntingtin, truncated N-terminal mutant and wild-type fragment, 
and chaperones and components of the proteolytic pathway are 
characteristic of HD neuropathology
Accumulation of mutant protein aggregates may be a result of 
impairment of the ubiquitin-proteosome pathway
Autophagic mechanisms are implicated in the clearance of protein 
aggregates
Transcriptional dysregulation
Aberrant nuclear localization of mutant toxic huntingtin fragments and 
their association with transcription factors
Dysregulation related to entrapment of transcriptional factors in protein 
aggregates
Excitotoxicity
excitotoxic neuron death in HD could result from a combination of 
increased glutamate and glutamate agonist release from cortical afferents
Mitochondrial dysfunction and altered energy metabolism
Selective inhibitors of complex ii of the mitochondrial electron transport 
chain, 3-NP and malonate, cause selective striatal neuronal loss similar 
to that seen in patients with HD
Multitude of bioenergetic defects have been reported in patients with HD
Changes in axonal transport and synaptic dysfunction
Normal huntingtin plays a role in axonal trafficking
Disruption of axonal transport contributes to pathologic process in HD
Abbreviations: HD, Huntington disease; NP, nitropropionic acid.
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Rating Scale in the setting of a family history of the dis-
ease. There may be other manifestations of HD at the time 
of presentation or prior to diagnosis based on behavioral 
and cognitive symptoms. A DNA test showing abnormal 
CAG expansion in the htt gene can be used to confirm the 
diagnosis in symptomatic individuals. With proper genetic 
counseling and at the patient’s request, DNA analysis can 
be performed in individuals at risk for developing HD 
under the care of experienced clinicians. There are many 
reasons why patients request presymptomatic testing, 
including financial planning, family planning, insurance 
decisions, and the need to know. Some people at risk for 
HD are reluctant to undergo testing and are brought into 
the clinic by future spouse, family, or others who believe 
testing should be performed. Under these circumstances 
or if the at-risk individual is likely to harm themselves or 
others based on the outcome of the test, genetic testing 
should be reconsidered.
There are ongoing studies to examine individuals who 
are gene positive but not yet symptomatic by motor criteria 
(TRACK-HD, Neurobiological Predictors of Huntington’s 
Disease Trial [PREDICT-HD], Prospective Huntington at Risk 
Observational Study [PHAROS]).40–43 There is also a study 
currently enrolling subjects with HD and their affected and 
unaffected family members to further understand biomarkers 
of disease and signs of onset (Cooperative Huntington’s 
Observational Research Trial [COHORT]).44 The focus of the 
COHORT study is not neuroimaging and anatomical measures 
but rather clinical measures and biological samples.
Subtle motor abnormalities have been associated with 
a smaller striatal volume and higher probability of disease 
diagnosis.40 Lower scores on the Hopkins Verbal  Learning 
Test-Revised were associated with closer proximity to 
diagnosis and smaller striatal volumes.44 Subjects with 
an expanded repeat and preclinical diagnosis of HD also 
had less accurate recognition of negative emotions.45 In 
addition, motor exam score, striatal volume, speeded fin-
ger tapping, self-timed finger tapping, word-list learning, 
and odor identifications in subjects in the PREDICT-HD 
study were all associated with the predicted time to diag-
nosis.46 Expansion-positive individuals reported more 
psychiatric symptoms (depression, anxiety, obsessive–
compulsiveness) than expansion-negative individuals.47 
The TRACK-HD study has confirmed some and expanded 
upon findings in PREDICT-HD in that presymptomatic 
subjects had significant changes in whole-brain volume, 
regional grey and white matter differences, impairment in 
a range of motor tasks, oculomotor findings, and cognitive 
and neuropsychiatric dysfunctions. The various motor and 
nonmotor measures on the neurological examination used 
to diagnose and track HD are included in the Unified Hun-
tington’s Disease Rating Scale.48 The scale is divided into 
6 sections: motor, cognitive, behavioral, and 3 functional 
scales (total functional capacity, functional checklist, and 
the independence scale).
Based on the guidelines published by the American 
 College of Genetics, patients with 40 or more repeats have 
100% penetrance.49 In other words, if patients have 40 or more 
copies of the gene, they will inevitably express the disease 
clinically. In patients with a CAG repeat length in the range of 
36–39, there is reduced penetrance with increased likelihood 
of expression occurring with longer length of repeats and 
with longer lifespan of the patient. Although there are case 
reports of patients who manifest HD in this range, patients 
with fewer than 36 repeats will generally not develop clini-
cal disease.50,51 Patients with an allele repeat size of 27–35 
have demonstrated meiotic instability, particularly in sperm, 
indicating that the following generation is at higher risk of 
inheriting an expanded number of repeats, increasing the 
risk of clinical disease. The length of repeat size correlates 
generally with the age of onset, but not necessarily with the 
severity or duration of disease.52
The course of the disease is typically 15–20 years, with 
dementia, mutism, dystonia, and bradykinesia predominating 
in end-stages. Patients with more dystonia and  swallowing 
issues may experience accelerated complications and, 
 therefore, shorter lifespan. Chorea may become a safety issue 
with larger amplitude movements causing injury or poor 
positioning. Frequent movements may result in skin injuries, 
infections, or even fractures and head trauma. Cause of death 
is typically related to complications of immobility, such as 
skin breakdown, pneumonia, cardiac disease, or infection. 
However, 25% of patients attempt suicide, which is a cause 
of death in 8%–9% of patients.53
Behavioral dyscontrol can be a severely disabling symptom 
of HD causing distress to the patient, family, and caregivers. 
Environmental approaches and cognitive interventions are 
the mainstay of treatments, but pharmacological agents 
can augment addressing disruptive behaviors. Depression, 
anxiety, aggressive, impulsive, and obsessive–compulsive 
behaviors are also frequently treated pharmacologically and 
require behavioral intervention, but caution should be used 
to avoid oversedation and apathy, already common in patients 
with HD. Although not well studied, cognitive approaches to 
treat behavior may be more effective than pharmacotherapy 
for some aspects of the disease.54
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Pharmacological treatment options
Many agents and surgical procedures have been evaluated 
in HD for their efficacy on suppressing chorea, including 
dopamine-depleting agents, dopamine antagonists, ben-
zodiazepines, glutamate antagonists, acetylcholinesterase 
inhibitors, dopamine agonists, antiseizure medications, 
cannabinoids, lithium, deep brain stimulation, and fetal cell 
transplantation.55–58 Pharmacological interventions typically 
address the hyperkinetic movement disorders that may be asso-
ciated with HD, such as chorea, dystonia, ballism, myoclonus, 
and tics. With regards to choose the agent, providers need 
to consider if there will be a positive or negative impact of 
the agent on psychiatric issues associated with HD, such as 
irritability, depression, anxiety, mania, apathy, obsessive–
compulsive disorder, or cognitive decline associated with 
HD. Adjunctive therapies, alternative and complementary 
therapies, behavioral plans, and cognitive interventions also 
may play a role in addressing the symptoms of HD and need 
to be considered when choosing medications.
Several excellent reviews have summarized the symptom-
atic treatment of HD.55–67 Overall, there is not enough evi-
dence available to guide long-term symptomatic treatment in 
HD, and double-blind and long-term studies assessing various 
treatment strategies in HD are needed.61 A Cochrane review 
of studies for the symptomatic treatment of HD examined 22 
trials that involved 1,254 different participants.62 Nine trials 
had a crossover design and 13 were conducted in parallel. The 
studies examined were of relatively short duration, ranging 
from 2 to 80 weeks. The number of trials examining various 
pharmacological interventions included antidopaminergic 
drugs (n = 5), glutamate receptor antagonists (n = 5), and 
energy metabolites (n = 5). Based on available evidence, 
the authors of the Cochrane review concluded that only 
tetrabenazine (TBZ) showed clear efficacy for the control 
of chorea, but “no statement can be made regarding the best 
medical practice for the control of motor and non-motor 
symptoms in HD”.
Tetrabenazine
TBZ is the only US Food and Drug Administration (FDA)-
approved drug for HD, indicated for the treatment of chorea 
associated with HD. In addition to the United States and 
Canada, TBZ is marketed in Australia, Denmark, France, 
Germany, Ireland, Israel, Italy, New Zealand,  Portugal, Spain, 
Switzerland, and United Kingdom. An excellent review 
of the chemistry, pharmacodynamics, pharmacokinetics, 
and mechanism of action is available in a previous issue of 
this journal.68 By reversibly inhibiting the central vesicular 
monoamine transporter type 2 (VMAT2), TBZ more selec-
tively depletes dopamine than norepinephrine.69,70 The highest 
binding density for TBZ is in the caudate nucleus, putamen, 
and nucleus accumbens, areas known to bear the brunt of 
pathology in HD.71,72 VMAT2 binding and monoamine deple-
tion by TBZ are reversible, last hours, and are not modified 
by long-term treatment.73,74 These features of the drug differ-
entiate it from the other dopamine-depleting agent, reserpine. 
Reserpine binds to both VMAT1 and VMAT2. While VMAT2 
is located solely in the central nervous system, VMAT1 is 
localized to the peripheral nervous system, accounting for 
some of the peripheral adverse effects, such as orthostatic 
hypotension and diarrhea. In contrast to TBZ, reserpine binds 
irreversibly to VMAT1 and VMAT2, making the duration 
of action considerably longer (hours vs days). In addition to 
TBZ, the 2 active metabolites, α- and β-dihydrotetrabenazine, 
have longer half-lives and are more highly bound to proteins 
than the parent compound.75–77
The efficacy of TBZ as an antichoreic drug was convinc-
ingly demonstrated in a double-blind, placebo-controlled trial 
conducted by the Huntington Study Group (HSG).78 Subjects 
were randomized to receive either TBZ (n = 54) or placebo 
(n = 30). TBZ was titrated weekly in 12.5 mg increments to 
a maximum of 100 mg/d or to the development of intoler-
able adverse effects. The primary efficacy outcome was the 
change from baseline in the total maximal chorea score of 
the Unified Huntington’s Disease Rating Scale.48 On this 
scale, chorea is graded from 0 to 4 (with 0 representing no 
chorea) for 7 body regions for a range in total scores from 
0 to 28. Compared with baseline, TBZ treatment resulted in 
a reduction of 5.0 units in chorea compared with a reduction 
of 1.5 units in the placebo group. About 50% of TBZ-treated 
subjects had a 6-point or greater improvement compared with 
7% of placebo recipients. There is also evidence to suggest 
continuous long-term efficacy and tolerability of TBZ in 
patients with HD.79–82
In the same study, the adverse events that occurred sig-
nificantly more frequently in the TBZ group included drowsi-
ness or somnolence, insomnia, depressed mood, agitation, 
akathisia, and hyperkinesia. However, by the conclusion of 
the maintenance phase, when subjects were presumably on 
optimal dosage, there were no significant differences between 
TBZ and placebo. Among subjects completing the study, the 
most common adverse event at the end of TBZ exposure was 
fatigue, reported by 7 subjects on TBZ (14.3%) and 2 on 
placebo (6.9%). There was 1 suicide in the double-blind 
study in a subject taking TBZ. Depression is common in 
HD and can be exacerbated by TBZ. However, attempted 
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or completed suicides in HD do not necessarily correlate 
with severity of depression and may be related to associ-
ated impulsiveness, obsessive–compulsive behavior, and a 
variety of socioeconomic factors. Nevertheless, all patients 
taking TBZ need to be monitored for signs of depression and 
suicidal ideation. Cognition in the TBZ group, as assessed 
by the Unified Huntington’s Disease Rating Scale, did not 
differ from that in the placebo group statistically, although 
both groups declined as expected over the course of the study. 
There were no HD-related quality-of-life measures included 
in the published TBZ studies.
The same group of study participants was given the 
opportunity to participate in an open-label extension study.82 
Seventy-five subjects were elected to participate initially, and 
at the end of the 3 phases of the extension study, 45 subjects 
had completed 80 additional weeks of treatment with TBZ. 
In the extension study, no new adverse effects were reported, 
and the drug was well tolerated, despite the attrition rate in the 
study (mostly for logistical reasons). There are a number of 
older open-label studies, primarily out of the Baylor College 
of Medicine database.80 The side effects and doses reported 
were fairly consistent with the double-blind study with the 
exception of insomnia. Chronic doses of the Baylor group 
were comparable with that in the long-term HSG study of 
62.5-mg total daily dose.
The safety of TBZ was evaluated in these studies, and 
in an additional study, the safety of sudden withdrawal after 
long-term use was assessed. The side effects are consistent 
among studies, and once the drug is titrated slowly to effect, 
the drug is well tolerated. Potential side effects include 
akathisia, depression, dizziness, fatigue, or parkinsonism 
(Table 3). During titration, patients may experience insomnia, 
somnolence, or gastrointestinal distress. If at any time side 
effects do occur, the dose can be lowered to the previously 
well-tolerated dose. Since the half-life is short, side effects 
tend to wane quickly. Withdrawal of TBZ results in a recur-
rence of chorea, not worse than before starting the drug.83 
There are no particular characteristics that may predispose 
patients to experience 1 or more side effects, but patients with 
a history of depression should be more closely monitored for 
changes in mood or impulsivity. Although it is listed in the 
product information sheet, TBZ does not cause and in fact 
may be an excellent treatment for tardive dyskinesia.
Other antichorea medications
Other medications that are commonly considered when 
treating chorea include dopamine antagonists, benzodiaz-
epines, and glutamate antagonists. Dopamine antagonists 
(neuroleptics) are perhaps the most commonly considered 
agents in the management of chorea and psychosis in patients 
with HD, but few double-blind, placebo-controlled studies 
evaluating the efficacy and safety of these agents have been 
published.84–86 None of the typical neuroleptics have been 
found to be effective in reducing chorea in placebo-controlled 
trials. However, in a study of haloperidol in 10 subjects, oral 
doses of 1.5–10 mg/d corresponded with at least a 30% reduc-
tion in chorea compared with baseline.87 The quantity and 
quality of these efficacy data need to be taken into account 
when considering the risks of using typical neuroleptics, 
particularly tardive dyskinesia. Apathy and akathisia, other 
potential adverse effects of the dopamine receptor blockers, 
can be particularly problematic in patients with HD, as they 
may not have the insight to recognize these problems or may 
wrongly attribute the symptoms to HD.
Owing to their presumed better tolerability, atypical 
 antipsychotics have recently been evaluated in HD.  Olanzapine 
has been used in small open-label studies to treat the motor 
symptoms of HD.88–92 The range of effect on chorea has been 
0%–66% reduction. There are no clinical trials of risperidone 
for HD, but a few reports suggest a positive effect on the disease 
with a tolerable adverse-effect profile.93–97 Quetiapine has been 
tried in multiple, small, uncontrolled, nonrandomized trials for 
HD with some success on both motor and psychiatric symp-
toms of HD.97–99 Clozapine was studied in patients with HD 
up to a dose of 150 mg/d for up to 31 days, but many adverse 
events, such as drowsiness, fatigue, anticholinergic symptoms, 
and walking difficulties, occurred without beneficial effects.100 
The newer atypical agent with multiple mechanisms of action, 
aripiprazole, has been found to be beneficial in a few small tri-
als with a  reduction in chorea equivalent to that with TBZ.101–103 
Table 3 Treatment-emergent side effects to monitor for when 
using tetrabenazine
During titration
insomnia
Somnolence
Gastrointestinal distress
During chronic therapy
Sedation
Depressed mood (and suicidality)
Anxiety
insomnia
Akathisia
Fatigue
Agitation
Falls
Dysphagia
Dysarthria
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Although aripiprazole may have fewer adverse effects on mood 
than TBZ, it is associated with tardive dyskinesia, similar to 
other typical and atypical neuroleptics.
The N-methyl D-aspartate-antagonist amantadine has 
been shown in controlled trials to significantly reduce chorea 
in patients with HD.104 Doses in the range of 400 mg/d or 
higher may be required for symptomatic benefit, but even 
in doses used to treat influenza, amantadine may increase 
irritability and aggressiveness.105 Because  riluzole retards 
striatal glutamate release and the pathological consequences 
in neurotoxic animal models of HD, multiple large trials 
have been conducted to determine if there is a possible 
neuroprotective effect. Riluzole was found to reduce chorea at 
a dose of 200 mg/d, but not 100 mg/d.106,107 Benzodiazepines 
are also frequently used clinically in patients with HD to treat 
anxiety and chorea, and there is limited evidence to suggest 
that higher doses of clonazepam (up to 5.5 mg/d) may be 
needed to suppress chorea.108 At this dose, sedation becomes 
a potential adverse effect. In a few short-term studies (hours), 
there is evidence that dopamine agonists may reduce the 
motor signs of HD.109–111 Although the pharmacological ratio-
nale for using dopamine agonists in the treatment of chorea 
is not clear, presumably they act by activating the presynaptic 
dopamine receptors leading to decreased dopamine turnover. 
More likely, however, is that the observed symptomatic 
effects are related to nonspecific or sedating effects.
For patients with the akinetic form of HD (Westphal 
variant), antiparkinsonian medications, such as levodopa, 
dopamine agonists, and amantadine, may be beneficial.112–115 
Botulinum toxin injections can also be considered for focal 
dystonia associated with HD.
Practical uses of TBZ
TBZ is formulated in 12.5- and 25-mg tablets. The medication 
is not available at local pharmacies but must be ordered 
through a central distribution center. Prescription  information 
can be found through the company’s Web site,  including 
prescribing information and obtaining the prescription 
form.116 Clinicians should note on the form that patients 
(or their guardian) must sign the release of information for 
the pharmacy to be able to communicate with the patient’s 
insurance company.
TBZ should be started at 12.5 mg/d, and every week, 
the dose should be increased by 12.5 mg/d, distributing the 
drug in 3-times daily dosing. Once patients reach twice-daily 
dose of 12.5 mg and daily dose of 25 mg (total daily dose of 
50 mg), as per the prescribing information, “before patients 
are given a daily dose of greater than 50 mg, they should be 
tested for the CYP2D6 gene to determine whether they are 
poor, extensive, or intermediate metabolizers”. This test can 
be costly (up to $3,000) and may or may not be covered by 
insurance. In addition, the drug is titrated to clinical effect, 
and the genotyping has no impact on the clinical assessment 
of the patient on the drug. Ultimately, it is up to the discre-
tion of the provider with the patient to determine if this test 
should be performed.
The goal of the effect of TBZ is to reduce chorea to a point 
that is acceptable to the patient. The goal should not be to 
eliminate chorea completely or to reduce chorea to a level that 
is acceptable to the caregiver or even physician treating the 
patient. The most common scenario is the titration of the 
drug to a side effect and then reducing the daily dose to a 
tolerated dose. Because HD is a progressive disease that 
changes over time, the dose of TBZ needs to be reassessed 
frequently (every 2–3 months). TBZ interacts with other 
CYP2D6 inhibitors, such as paroxetine. There is no evidence 
if TBZ can be used safely or effectively with neuroleptics or 
other commonly used medications for chorea.
Conclusion
Until clear neuroprotective strategies are found, clinicians 
can address the symptoms of patients with this devastating 
disease. The most and best evidence for treating troublesome 
chorea leads toward TBZ, but other abnormal involuntary 
movements, cognition, affective disorders, and behavioral 
dyscontrol all need to be considered when choosing therapies 
for patients. Further studies to determine interactions and 
combination therapy of TBZ need to be completed, as most 
patients need multiple medications to adequately address 
symptoms. Other issues related to HD also need to be studied 
more closely when treating patient with TBZ. Although there 
is one FDA-approved option at this time and other medica-
tions hopefully soon to be available, there are not enough 
effective, safe interventions that can be offered to our patients 
and their families with this invariably fatal disease.
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